Viskase Holdings, Inc. 8-K

What Happened
Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals) announced on May 5, 2026 that its Board adopted a Section 382 Rights Agreement (Rights Agreement) and declared a dividend of one Right for each outstanding share of common stock (record date May 15, 2026). The Rights, issued under a certificate of designation filed May 5, 2026, are intended to deter transactions that could trigger an "ownership change" under Section 382 of the Internal Revenue Code and thereby limit the Company’s ability to use its net operating loss carryforwards (NOLs).

Key Details

• Rights declaration date: April 30, 2026; record date for the dividend of Rights: May 15, 2026. Certificate of Designation filed in Delaware on May 5, 2026. Press release issued May 5, 2026.
• One Right is issued per outstanding share of common stock. Each Right (on exercise) entitles the holder to purchase 1/1,000 of a share of Series A‑2 Junior Participating Preferred Stock at $30.00 per Right (subject to adjustment).
• The Rights become exercisable on a Distribution Date triggered after a Stock Acquisition Date (generally when a person/group becomes an "Acquiring Person" by obtaining 4.9% or more). Existing holders at or above 4.9% as of the Rights Declaration Date are grandfathered at their current level.
• Flip‑in protection: after a Flip‑in Event, each non‑void Right allows purchase of common stock with market value equal to 2x the exercise price (i.e., $60 of stock for $30 paid). Flip‑over protection applies upon certain mergers or asset sales.
• Other terms: Rights agent Continental Stock Transfer & Trust Company; Rights may be redeemed by the Company for $0.01 per Right before a Stock Acquisition Date or final expiration; Final Expiration Date is May 4, 2029 (or earlier if shareholder approval is not obtained by May 4, 2027 or other specified events). Preferred share features include 1,000 votes per share and substantial dividend/liquidation provisions tied to 1,000× common share economics.

Why It Matters
The Rights Agreement is a defensive measure aimed at preserving the value of Viskase’s tax attributes (NOLs) by discouraging any investor or group from acquiring enough stock to trigger a Section 382 ownership change. For investors, this can reduce the likelihood of a hostile takeover or rapid accumulation of shares that would materially limit the Company’s future tax benefits. The Rights also give the Board flexibility to redeem or exchange the Rights and to exempt certain transactions or holders (including board‑approved exemptions and specified categories), which may affect how potential investors or activists approach acquiring a stake.